Nursing care
Antiplatelet Agents: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Antiplatelet agents reduce clot formation by stopping platelets from aggregating, and are used to prevent arterial events such as stroke and myocardial infarction. Unlike warfarin, they are not monitored with INR — bleeding time and clinical signs of bleeding matter more. They are held before surgery on a schedule that differs by drug, from a few days for aspirin to a week or more for clopidogrel.
What it does and why it is prescribed
Antiplatelet agents interfere with the platelet's ability to aggregate rather than acting on the coagulation cascade the way anticoagulants do. Aspirin irreversibly inhibits cyclooxygenase-1, blocking thromboxane A2 production for the life of the platelet, roughly seven to ten days. Clopidogrel and other P2Y12 inhibitors block the ADP receptor on the platelet surface, also irreversibly.
These drugs are prescribed to prevent arterial thrombotic events — ischaemic stroke, myocardial infarction, and occlusion of coronary or peripheral stents. Dual antiplatelet therapy, typically aspirin plus a P2Y12 inhibitor, is standard after placement of a drug-eluting coronary stent for a defined duration set by the cardiologist, and stopping it early carries a real risk of stent thrombosis.
Nursing considerations before giving it
Ask about any planned procedures, recent bleeding, peptic ulcer history, and other drugs that affect haemostasis, including NSAIDs, SSRIs, and anticoagulants. Because these drugs act on platelets rather than clotting factors, the usual coagulation panel will not reflect their effect, so history-taking carries more weight here than it does with warfarin.
Confirm the indication and duration, particularly for dual antiplatelet therapy after stenting, since the prescriber's stop date is a clinical decision tied to stent endothelialisation, not a default to be adjusted on the ward without cardiology input.
What to monitor
INR and PT are not useful for antiplatelet agents; they measure the clotting cascade, which these drugs do not touch. Where monitoring is done, it is bleeding time or platelet function assays, and in practice most routine care relies on clinical assessment rather than a lab number.
Watch for overt bleeding — gums, epistaxis, bruising, blood in stool or urine — and for a falling haemoglobin or haematocrit on serial bloods. In a patient on dual therapy after a stent, also monitor for signs of stent thrombosis, such as recurrent chest pain, since the risk of stopping the drug too early is as real as the risk of bleeding from continuing it.
Side effects versus adverse effects
Expected side effects include easy bruising, mild gum bleeding on brushing, and gastrointestinal upset, which is more pronounced with aspirin because of its direct effect on the gastric mucosa. Dyspepsia and occult blood loss are common enough with long-term aspirin use that many patients are co-prescribed a proton pump inhibitor.
Adverse effects that change management are gastrointestinal haemorrhage, intracranial bleeding, and thrombotic thrombocytopenic purpura, a rare but serious reaction reported with clopidogrel and ticlopidine. Any sign of major bleeding — melena, haematemesis, a sudden neurological change — is an adverse effect requiring immediate escalation, not routine documentation.
What to hold for and when to call
Hold before surgery on a schedule set by drug and platelet lifespan: aspirin is typically stopped around five to seven days before major elective surgery, clopidogrel around five to seven days, and prasugrel or ticagrelor on similarly staggered timelines specific to each agent, because platelets do not recover function until new ones are made. The exact window is set by the surgical and cardiology teams together, particularly in a patient with a recent stent, since stopping too early risks thrombosis and continuing too close to surgery risks bleeding.
Call for any sign of major bleeding, a haemoglobin drop, black or tarry stools, or neurological changes suggesting intracranial haemorrhage. Also call before withholding a dose around a procedure if there is no documented hold order, rather than assuming it is safe to skip — for a patient with a recent stent, an unauthorised hold is itself a hazard.
Patient teaching
Teach patients to watch for and report unusual bruising, bleeding gums, blood in urine or stool, and to use a soft toothbrush and electric razor to reduce minor bleeding. Tell them to mention the medication to every prescriber and dentist, since even minor procedures may require a planned hold.
For patients on dual antiplatelet therapy after a stent, stress that stopping either drug early without cardiology approval — even for a dental visit or a course of NSAIDs bought over the counter — carries a real risk of stent thrombosis. Advise avoiding routine NSAID use, since it compounds bleeding risk, and to disclose the drug before starting any new medication, including herbal supplements such as ginkgo or fish oil.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Do antiplatelet agents need INR monitoring?
No. INR reflects the clotting cascade, which antiplatelet drugs do not affect. They act on platelet aggregation instead, so monitoring relies on bleeding time, platelet function testing where available, and clinical assessment for bleeding.
How long before surgery is clopidogrel held?
Typically around five to seven days, though the exact timing is set by the surgical and cardiology teams, especially if the patient has a recent coronary stent, since platelets need to be replaced rather than simply cleared from circulation.
Why is aspirin held for a shorter or similar time to clopidogrel despite both being irreversible?
Both inhibit platelets for the platelet's full lifespan, around seven to ten days, so hold times are similar in principle. The exact number of days used clinically varies by institution and by the bleeding risk of the specific procedure.
Why is stopping dual antiplatelet therapy early dangerous after a stent?
The stent surface needs time to endothelialise, and until it does, exposed metal is a strong trigger for clot formation. Stopping aspirin or the P2Y12 inhibitor before the prescribed duration significantly raises the risk of stent thrombosis, which can present as a sudden myocardial infarction.
More on pharmacology
Guides on this